Follow us on:

Avacta Group transfer technology to BBI Solutions for manufacture of COVID-19 test (Interview)

Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the appointment of BBI Solutions as manufacturing partner for the COVID-19 test. Alastair talk us through the details, how the prototype is working and the next steps in bringing it to market. Also discussed is the existing agreement with Daewoong Pharmaceutical which has been expanded to include the SARS-CoV-2 neutralising Affimer reagents and the development of the high throughput COVID-19 test with Adeptrix.

Avacta Group also announced that it has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva.

Find more news, interviews, share price & company profile here for:Avacta Group Plc

Share this interview

Other Interviews

More News

Avacta Group Potential for a COVID-19 Therapy May 15, 2020
Avacta Group Ships SARS-COV-2 Affimer Reagents to Cytiva and Adeptrix May 11, 2020
Avacta Group Strong revenue growth and cash position and multiple long term growth opportunities May 6, 2020
Avacta Group COVID-19 Antigen Diagnostic Collaboration with Adeptrix May 1, 2020
Avacta Group / Cytiva Partnership Ahead of Schedule for COVID-19 Antigen Rapid Test April 22, 2020
Avacta and Cytiva collaborating on COVID-19 Rapid Test April 8, 2020
Avacta Group Proposed Placing to raise £3.75 million April 6, 2020
Avacta Group plc To raise £2m to secure further significant drug development partnerships April 2, 2020
Avacta Group Shareholder and Investor Meeting and Presentation March 10, 2020
Avacta Group to hold Analyst Briefing February 13, 2020

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.